Treatment with teclistamab, administered subcutaneously at a dose of 1500 µg/kg once weekly, led to a high response rate and an encouraging safety profile in patients with relapsed/refractory multiple myeloma.
Recent Content
- ASH 2024: Cilta-Cel Achieves Sustained MRD Negativity in Patients With Multiple Myeloma
- Emerging BCMA-Directed Therapies in Multiple Myeloma: Bispecific Antibodies and CAR T-Cell Therapies
- Advancements in Multiple Myeloma Therapies and Operational Insights in Oncology Clinical Trials
- Darzalex Regimen May Improve MRD Responses in Multiple Myeloma
- Elranatamab monotherapy in the real-word setting in relapsed-refractory multiple myeloma: results of the French compassionate use program on behalf of the IFM
- Hexamethylene amiloride induces lysosome-mediated cell death in multiple myeloma through transcription factor E3
- Global disparities in drug-related adverse events of patients with multiple myeloma: a pharmacovigilance study
- Black Patients With Myeloma Face Taste, Skin Side Effects from Talvey
- ASH 2024: Expert Discusses Challenges, Future Research Opportunities With Bispecific Antibodies in Multiple Myeloma
- Blenrep Combo Improves Survival in Relapsed/Refractory Multiple Myeloma